DermBiont
DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and based in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to compete with pathogenic organisms such as fungi, bacteria, and viruses. DermBiont's product portfolio includes therapeutics for various skin conditions, including fungal infections and hyperpigmentation disorders like melasma, as well as treatments for seborrheic keratoses. The company employs a unique discovery platform that utilizes its skin microbiome library, integrating prebiotics, probiotics, and postbiotics to develop innovative topical therapies with defined mechanisms of action.
Top Stages
2 past transactions
Chromaderm
Acquisition in 2021
Chromaderm develops a topical inhibitor of melanin production as a first-in-class therapy for skin brightening, melasma, and other skin diseases associated with increased melanin production.
SeylanMED
Acquisition in 2020
SeylanMED is a biotechnology company focused on developing targeted therapies for Seborrheic Keratosis (SK). Their primary goal is to create a topical Akt inhibitor, which would be the first of its kind treatment for SK. The company's lead drug candidate, SM-020, represents a novel molecularly-targeted approach to treating this condition. SeylanMED has secured funding from angel investors, including board-certified dermatologists, and is currently operating in stealth mode.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.